XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack). XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack). "Many Americans have a very limited understanding of the basic facts about diabetes, as well as the serious consequences for health that accompany the disease," commented Sue McLaughlin, RD, CDE, President, Health Care & Education, American Diabetes Association, in a media alert. She blames the problem on a combination of factors including denial of the disease and promotion of inaccurate ...